Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest ShangPharma Corporation Stories

2014-01-13 08:30:25

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and...

2013-10-25 12:24:16

SHANGHAI, Oct. 25, 2013 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Art Taveras will join the company as President and Chief Scientific Officer (CSO). Dr. Taveras brings extensive pharmaceutical leadership and technical expertise in all aspects of Drug Discovery, Chemistry R&D and Pharmaceutical Development having served as a Pharmaceutical and Biotech Executive during his 24-year career. As President and CSO, Dr. Taveras will establish ShangPharma as...

2013-03-28 04:20:43

SHANGHAI, March 28, 2013 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) (the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced the completion of the merger contemplated by the previously announced Agreement and Plan of Merger dated December 21, 2012 (the "Merger Agreement"), by and among the Company, ShangPharma Holdings Limited ("Holdings"), ShangPharma Parent Limited ("Parent") and ShangPharma...

2013-03-20 04:20:55

SHANGHAI, March 20, 2013 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) (the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that, at an extraordinary general meeting held today, the Company's shareholders voted in favor of the proposal to approve the previously announced Agreement and Plan of Merger dated December 21, 2012 (the "Merger Agreement"), by and among the Company, ShangPharma Holdings Limited...

2013-02-25 08:22:41

SHANGHAI, Feb. 25, 2013 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) (the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held on March 20, 2013, at 10:00 am (Hong Kong time), at 42nd Floor, Edinburgh Tower, The Landmark, 15 Queen's Road, Central, Hong Kong, to consider and vote on, among others, the proposal to...

2012-12-21 08:23:24

SHANGHAI, China, Dec. 21, 2012 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) (the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that the Company has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with ShangPharma Holdings Limited ("Holdings"), ShangPharma Parent Limited ("Parent") and ShangPharma Merger Sub Limited ("Merger Sub"), pursuant to which Parent will acquire the...

2012-11-20 08:25:49

SHANGHAI, Nov. 20, 2012 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the third quarter ended September 30, 2012. Third Quarter 2012 Highlights Net revenues increased by 10.6% year-over-year to $31.9 million. Net revenues from full-time-equivalent ("FTE")-based services increased by 14.6%...

2012-11-06 08:26:49

SHANGHAI, Nov. 6, 2012 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2012, on November 20, 2012. Management will host a conference call to discuss the results at 8:00AM U.S. Eastern Time on November 20, 2012 (9:00PM Beijing Time on...

2012-09-13 02:26:32

SHANGHAI, Sept. 13, 2012 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Harbour Antibodies ("Harbour"), a Dutch biotechnology company, today announced that they have entered into a collaborative licensing agreement under which ShangPharma will develop therapeutic antibody candidates for its customers using Harbour's transgenic mouse-based fully human...

2012-08-20 02:28:24

SHANGHAI, Aug. 20, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the second quarter ended June 30, 2012. Second Quarter 2012 Highlights Net revenues increased by 15.7% year-over-year to $31.8 million. Net revenues from the Company's top-10 customers increased by 21.3%...